Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC

NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC

PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).

Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud Allegations

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update.

Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Revance Therapeutics, Inc. (RVNC)

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Revance Therapeutics, Inc. (RVNC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Revance Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Revance Therapeutics, Inc. (RVNC)

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Revance Therapeutics, Inc. Being Investigated on Behalf of Revance Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Revance Therapeutics, Inc. (RVNC) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

ATTENTION RVNC SHAREHOLDERS: Investors who lost money on Revance Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

Lost Money on Revance Therapeutics, Inc. (RVNC)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Shareholder Rights Advocates at Levi & Korsinsky Investigate Revance Therapeutics, Inc. (RVNC) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".

Shareholders That Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky About Securities Fraud Investigation - RVNC

Revance Therapeutics, Inc. Being Investigated on Behalf of Revance Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a notice to remedy alleged material breach.

The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required ef.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Revance investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

The heavy selling pressure might have exhausted for Revance Therapeutics (RVNC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround

The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $6.66 in cash for each share of Revance that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

MILWAUKEE , Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation https://www.ademilaw.com/case/revance-therapeutics-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Revance Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Revance Therapeutics , Inc. ( Nasdaq : RVNC ) , relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNC

The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Revance Therapeutics Stock (RVNC)